ClinicalTrials.gg
CompletedNCT00383370Updated Apr 21, 2011

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

A Phase 1 interventional study of VEGF Trap and VEGF Trap in Neovascular Age Related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-21.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
61st of 67
20 · median 54
Started
2006
with 1 other
Phase 1
6 of 67
1 open now
Registered
3rd of 67
by date
Lead sponsor
10 of 67
Regeneron Pharmaceuticals

Among the 67 studies testing aflibercept in Macular Degeneration, this one is the 61st largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 1, and was the 3rd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

To assess the safety and tolerability of repeated intravitreal (ITV) administration of VEGF Trap.

Read the detailed description

A double-masked study in which approximately 12 subjects will receive ITV injections of VEGF Trap every 4 weeks for a total of 3 doses. Once the subjects have received the 3 doses allowed in this study, they will be evaluated every 4 weeks for continued dosing of VEGF Trap for an additional 9 months.

03

Conditions studied

  • Neovascular Age Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subfoveal CNV secondary to AMD.
  • Central retinal (including lesion) thickness ≥ 250 µm as measured by OCT.
  • ETDRS best-corrected visual acuity (BCVA) of 20/40 to 20/400 (73 to 20 letters)

Exclusion criteria

Exclusion Criteria:

  • No prior treatment with the following in the study eye:

    • Subfoveal thermal laser therapy;
    • Submacular surgery or other surgical intervention for the treatment of AMD;
    • Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1 (Visit 2);
    • PDT or ITV administration of triamcinolone acetonide or any other within 12 weeks prior to Day 1 (Visit 2);
    • Pegaptanib sodium within 8 weeks of Day 1 (Visit 2);
    • Juxtascleral steroids or anecortave acetate within 180 Days (6 months) prior to Day 1 (visit 2);
    • Prior systemic or intravitreal treatment with VEGF Trap or bevacizumab;
    • Any agent for the treatment of eye disease within 12 weeks of Day 1 (Visit 2)
  • History of any vitreous hemorrhage within 4 weeks prior to baseline injection visit.
  • Aphakia or pseudophakia with the absence of a posterior capsule (unless it occurred as a result of a yttrium aluminum garnet [YAG] capsulotomy).
  • Significant subfoveal atrophy or scarring.
  • Any condition or laboratory abnormality that, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the subject's appropriate participation in this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    ITV-1

    VEGF Trap formulation 1

    Drug: VEGF Trap

  • Experimental
    ITV-2

    VEGF Trap formulation 2

    Drug: VEGF Trap

  • Experimental
    ITV-2 OL

    VEGF Trap formulation 2 open label, higher concentration

    Biological: VEGF Trap

Interventions

  • VEGF Trap formulation 1, ITV-1

    Also known as: ITV-1

  • BiologicalVEGF Trap

    VEGF Trap formulation 2 at higher concentration in Open label cohort

    Also known as: ITV-2

06

What researchers measure

Primary outcomes

  1. The primary endpoint of the study will be safety and tolerability of the study treatment at Week 12 as assessed by ophthalmic examination and reporting of AEs.

    Time frame: 12 weeks

07

Study locations

6 sites
  • Fort Myers, Florida 33907, United States
  • Wichita, Kansas 67214, United States
  • Hagerstown, Maryland 21740, United States
  • Columbia, South Carolina 29169, United States
  • Austin, Texas 78705, United States
  • McAllen, Texas 78503, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Sep 2007 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2006
First posted
Oct 3, 2006
Start
Oct 2006
Primary completionActual
Sep 2007
CompletionActual
Jul 2008
Last update
Apr 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00383370
First posted
Oct 3, 2006
Start date
Oct 2006
Primary completion
Sep 2007
Completion
Jul 2008
Last update
Apr 21, 2011

Study contacts

Avner Ingerman, MD
study director · Regeneron Pharmaceutical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion